Scientific Focus
Gluten Intolerance and Enteric Infection Affects Millions
The Milky Way Life Science team has over 25 years of experience in the medical research of colostrum. It is using this expertise to unlock the full range of colostrum health benefits to address two disease states: Gluten Intolerance and Enteric Infections (intestinal infections) in children.
7% of US Population Suffers from Gluten Intolerence
When it comes Gluten Intolerance, there is no treatment. The only thing for patients to do is follow a strict gluten-free diet. Yet gluten is everywhere and in everything, including toothpaste, spices, lipstick, and vitamins. 32% of food served in restaurants labeled 'gluten free' contain gluten (The American Journal of Gastroenterology, 2019). Conservative estimates state 7% of the US population suffers from a Glueten Intollerance, or 32 million people.
Entreric Infections: A Worldwide Culprit
Milky Way Life Sciences is addressing significant medical conditions that are found around the world, such as Stunted Growth Syndrome (dwarfism). Dwarfism causes impaired cognition, increased risk of heart disease, stroke, Type 2 Diabetes, and premature death. In 2019 alone 21% of children under 5 in Asia, Africa, and Latin America suffered from Stunted Growth Syndrome, or 144 million children (World Health Organization). The cause of Stunted Growth Syndrome is intestinal infection - just one of the infections Milky Way Life Sciences is addressing.
R&D Pipeline
Experience, expertise, and vision. These assets set Milky Way Life Sciences apart. Its R&D pipeline is based on a core technology platform of colostrum.